Previous close | 0.0100 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 0.0100 |
Strike | 55.00 |
Expiry date | 2024-05-17 |
Day's range | 0.0100 - 0.0100 |
Contract range | N/A |
Volume | |
Open interest | 73 |
Moderna's second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Gerry Smith reports on Bloomberg Television.
Key Insights Significantly high institutional ownership implies Moderna's stock price is sensitive to their trading...
(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t Track‘Seriously Underwater’ Home Mortgages Tick Up Across th